The results were analyzed with Wilcoxon test and p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: To determine the effects of nebivolol on diastolic functions of the left ventricle in the hypertensive patients in the early treatment period.
📊
Key Findings & Data:Methods: Twenty patients with mild to moderate hypertension taking daily 5 mg of nebivolol were assessed by using Doppler echocardiography before and after 6-week drug treatment period.
💡
Conclusion & Impact:The results were analyzed with Wilcoxon test and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: To determine the effects of nebivolol on diastolic functions of the left ventricle in the hypertensive patients in the early treatment period. Methods: Twenty patients with mild to moderate hypertension taking daily 5 mg of nebivolol were assessed by using Doppler echocardiography before and after 6-week drug treatment period. The results were analyzed with Wilcoxon test and p
Özet
Amaç: Nebivololün hipertansif hastalarda sol ventrikülün erken dönem diyastolik fonksiyonları üzerindeki etkisini değerlendirmek.Yöntemler: Hafif–orta hipertansiyonu olan 20 hastanın günlük 5 mg Nebivolol ile tedavi öncesi ve 6 hafta sonra Doppler ekokardiyografi ile sol ventrikül diyastolik fonksiyonları değerlendirildi. Sonuçlar Wilcoxon testi ile değerlendirildi ve p
🔖
Cite This Article
ÇELİK, T., DEMİRALP, E., ÖZMEN, N., CEBECİ, B. S., DİNÇTÜRK, M., KARDEŞOĞLU, E., IŞILAK, Z., ULUSOY, R. E. (2022). Short-term effect of nebivolol on the left ventricular diastolic function. Anadolu Kardiyoloji Dergisi, Cilt: 4 - Sayı: 4, 323–326. https://ajindex.com/articles/437482
Pauwels PJ, Gommeren W, Van Lommen G, Janssen PAJ, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blokers. Mol Pharmacol 1988; 34: 843-51
Van de Water A, Janssens W, Van Nueten J, Xhonneoux R, De Cree L. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective, b1- adrenergic antagonist J Cardiovasc Pharmacol 1988; 2: 552-63 3. Janssens WJ, Van de Water A, Xhonneux R, Reneman RS, Van Nueten JM, Janssen P. A. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989; 159: 89-95
Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204
Cockoft JR, Chowienczyk PJ, Brett AE, et al. Nebivolol vasodilates human forearm vasculature; evidence for an L –arginine/NO-dependent mechanism J Pharmacol Exp Ther 1995; 274: 1067-71
Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with hypertension, Br J Clin Pharmacol 1999; 48: 460-3
Stoleru L, Wijns W, van Eyll C, Bouvy T, van Nueten L, Pouleur H. Effects of D-nebivolol and L-nebiviolol on left ventricular systolic and diastolic function; comparison with D-L- nebivolol and atenolol. J Cardiovasc Pharmacol 1993; 2; 183-90
Rousseau MF, Chapelle F, Van Eyll C, et al. Medium-term effects of b-blockade on left ventricular mechanism; a double –blind, placebo- controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Failure 1996; 21; 15-23
Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-63
De Cree J, Geukens H, Verhaegen H. Non–invasive cardiac heamodynamics of nebivolol. An overview. Drug Invest 1991; 3; 40-50
Goldstein M, Vincent JL, De Smet JM, et al. Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function. J Cardiovasc Pharmacol 1993; 22; 253-8
Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-100
Himmelman A, Hedner T, Lundgren B, Snoeck E. Haemodynamic effects and pharmacokinetics